Editor Note: For more information about this release, please scroll to bottom.
LONDON, July 10, 2014 /PRNewswire/ --
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average finished the session at 16,985.61, up 0.47% and the S&P 500 closed at 1,972.83, up 0.46%. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.38% higher at 712.05, and the index has gained 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Team Health Holdings Inc. (NYSE:TMH), Antares Pharma Inc. (NASDAQ:ATRS), Illumina Inc. (NASDAQ:ILMN) and Questcor Pharmaceuticals Inc. (NASDAQ:QCOR). Free technical research on TMH, ATRS, ILMN and QCOR can be downloaded upon signing up at:
On Wednesday, shares in Team Health Holdings Inc. gained 0.92%, closing the session at $50.26. A total of 0.66 million shares were traded, which was above its three months average volume of 0.55 million shares. The stock moved between $49.46 and $50.54 during the session. Team Health Holdings Inc.'s stock has fallen by 1.41% in the previous three trading sessions and 2.79% in the last one month, while the company's shares have gained 10.34% from the beginning of 2014. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $49.59 is above its 200-day moving average of $45.77. Additionally, Team Health Holdings Inc.'s stock traded at a PE ratio of 32.97 and has a Relative Strength Index (RSI) of 48.57. Sign up today to read free research on TMH at:
Shares in Antares Pharma Inc. advanced 1.14% on Wednesday, ending the day at $2.67. The stock recorded a trading volume of 1.04 million shares, near its three months average volume of 1.41 million shares. The company's stock oscillated between $2.64 and $2.71 during the session. Shares in Antares Pharma Inc. have lost 5.99% in the previous three trading sessions and 12.17% in the last one month. Additionally, the company's shares are down 40.28% since the start of this year. Antares Pharma Inc.'s shares are trading below their 50-day and 200-day moving averages of $2.92 and $3.81, respectively. Furthermore, the company's stock has an RSI of 36.13. Sign up today to read free research on ATRS at:
Illumina Inc.'s stock fluctuated between $170.33 and $176.34 before ending Wednesday's session 2.51% higher at $175.23. The company's stock reported a trading volume of 1.77 million shares, which was close to its three months average volume of 1.78 million shares. Shares of the company traded at a PE ratio of 117.11. Over the last one month and on YTD basis, Illumina Inc.'s stock has gained 2.26% and 58.45%, respectively. However, the company's stock has declined 4.17% in the previous three trading sessions. Illumina Inc.'s stock is trading above its 50-day and 200-day moving averages of $159.80 and $131.83, respectively. Moreover, the company's shares have an RSI of 50.63. Sign up today to read free research on ILMN at:
On Wednesday, shares in Questcor Pharmaceuticals Inc. recorded a trading volume of 0.98 million shares, below its three months average volume of 2.06 million shares. The finished the day at $91.60, which was 1.05% lower its previous day's closing of $92.57, and registered an intraday range of $91.09 and $93.54. Shares in Questcor Pharmaceuticals Inc. have advanced 2.58% in the last one month and 68.23% on YTD basis, although, the company's shares have lost 3.58% in the previous three trading sessions. Shares in Questcor Pharmaceuticals Inc. are trading above their 50-day and 200-day moving averages of $89.23 and $69.67, respectively. Furthermore, the company's stock traded at a PE ratio of 17.17 and has an RSI of 55.38. Sign up today to read free research on QCOR at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.